 DURECT Corporation Nasdaq: DRRX today announced that Gilead Sciences, Inc., Gilead has provided notice that, effective as of December 22, 2020, it is terminating the License Agreement dated July 19, 2019 and a related RD; agreement between Gilead and DURECT related to the development and commercialization of a long-acting injectable HIV investigational product utilizing DURECTs SABER technology. 